WuXi Biologics boosts issued share capital through option exercises

WuXi Biologics (Cayman) Inc. reported changes in its issued ordinary shares, detailing an increase from 4,107,272,633 on November 19, 2025, to 4,113,734,981 on November 25, 2025. This reflects a net increase of 6,462,348 shares.

The increases primarily stem from the exercise of share options under the Pre-IPO Share Option Scheme adopted on January 5, 2016. On November 20, 2025, 4,000 new shares were issued at HK$1.67. Further issuances occurred on November 21, 2025, with 318,100 shares at HK$1.3, and on November 24, 2025, with 90,248 shares at HK$2.1.

Additional issuances on November 25, 2025, included 50,000 shares at HK$1.83 and a substantial issuance of 6,000,000 shares at HK$1.29. These transactions relate to share awards or options granted to participants and directors. The company confirmed that all necessary conditions and legal requirements for these issuances have been met. There were no shares redeemed or repurchased for cancellation as of the closing balance date.